<![CDATA[How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?]]>
Although R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone) has long served as the frontline backbone for diffuse large B-cell lymphoma (DLBCL), a subset of patients, particularly those with non–germinal center B-cell– …